Iovance Biotherapeutics, Inc.
IOVA
$2.83
$0.155.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.32M | 73.69M | 58.56M | 31.11M | 715.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.32M | 73.69M | 58.56M | 31.11M | 715.00K |
| Cost of Revenue | 49.74M | 45.54M | 39.82M | 31.37M | 7.26M |
| Gross Profit | -417.00K | 28.15M | 18.73M | -262.00K | -6.55M |
| SG&A Expenses | 43.93M | 42.50M | 39.55M | 39.57M | 31.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.55M | 160.27M | 147.62M | 133.02M | 118.44M |
| Operating Income | -121.22M | -86.58M | -89.07M | -101.91M | -117.72M |
| Income Before Tax | -118.00M | -77.00M | -85.06M | -98.56M | -114.38M |
| Income Tax Expenses | -1.84M | 1.56M | -1.52M | -1.46M | -1.41M |
| Earnings from Continuing Operations | -116.16M | -78.56M | -83.54M | -97.10M | -112.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.16M | -78.56M | -83.54M | -97.10M | -112.98M |
| EBIT | -121.22M | -86.58M | -89.07M | -101.91M | -117.72M |
| EBITDA | -113.03M | -78.06M | -80.50M | -93.44M | -110.11M |
| EPS Basic | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 |
| Normalized Basic EPS | -0.23 | -0.16 | -0.18 | -0.22 | -0.27 |
| EPS Diluted | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 |
| Normalized Diluted EPS | -0.23 | -0.16 | -0.18 | -0.22 | -0.27 |
| Average Basic Shares Outstanding | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M |
| Average Diluted Shares Outstanding | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |